Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.16 USD | -20.00% |
|
0.00% | +3.83% |
Jun. 14 | Renalytix's Diabetes, Kidney Disease Test Gets Medicare Final Coverage Determination | MT |
Jun. 14 | Renalytix Secures Medicare's Final Local Coverage Determination for Kidney Disease Test | MT |
Financials (USD)
Sales 2024 * | 2.5M | Sales 2025 * | 6.98M | Capitalization | 34.24M |
---|---|---|---|---|---|
Net income 2024 * | -32M | Net income 2025 * | -24M | EV / Sales 2024 * | 13.7 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 4.91 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 102 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 61.53% |
Latest transcript on Renalytix Plc
1 day | -20.00% | ||
Current month | -42.86% | ||
1 month | -42.86% | ||
3 months | -74.24% | ||
6 months | +3.83% | ||
Current year | +3.83% |
![Extreme 0.16](/images/extremecours_fleche.png)
![Extreme 0.16](/images/extremecours_fleche.png)
![Extreme 0.1541](/images/extremecours_fleche.png)
![Extreme 0.1541](/images/extremecours_fleche.png)
![Extreme 0.1541](/images/extremecours_fleche.png)
![Extreme 0.1541](/images/extremecours_fleche.png)
Managers | Title | Age | Since |
---|---|---|---|
James McCullough
FOU | Founder | 56 | 18-03-14 |
Howard Doran
PSD | President | 63 | 23-08-31 |
Fergus Fleming
CTO | Chief Tech/Sci/R&D Officer | 57 | 18-03-14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Daniel Levangie
BRD | Director/Board Member | 73 | 21-08-29 |
Chairman | 72 | 18-03-14 | |
James McCullough
FOU | Founder | 56 | 18-03-14 |
![Consensus](/images/consensus_flch.gif)
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-34.39% | 14.7B | |
-52.73% | 2.33B | |
+24.29% | 1.96B | |
-8.30% | 1.52B | |
+21.24% | 1.24B | |
-21.39% | 904M | |
-34.32% | 750M | |
+1.33% | 784M | |
-28.73% | 597M |
- Stock Market
- Equities
- RENX Stock
- RTNXF Stock